drugset / Trial / NCT01886053
A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects，and explore its therapeutic dose.
Timeline
- Start
- 2011-04
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ertapenem | Small molecule | 1000 mg | — |
| Subject | Faropenem | Small molecule | 2400 mg | — |
Indications
No indication recorded.